NEW YORK--(BUSINESS WIRE)--
Third paragraph, first sentence of release should read: You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE: MNK) for $18.00 in cash per share of Sucampo stock (instead of ... $28.00 in cash per share of Sucampo stock).
The corrected release reads:
INVESTOR ALERT: LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF AN INVESTIGATION CONCERNING WHETHER THE SALE OF SUCAMPO PHARMACEUTICALS, INC. TO MALLINCKRODT PLC IS FAIR TO SHAREHOLDERS
The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Sucampo Pharmaceuticals, Inc. (“Sucampo” or the “Company”) (NASDAQ GM: SCMP) stock prior to December 27, 2017.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE: MNK) for $18.00 in cash per share of Sucampo stock. To learn more about the action and your rights, go to:
http://www.zlk.com/mna/sucampo-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The investigation concerns whether the Board of Sucampo breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Mallinckrodt plc is underpaying for Sucampo shares, thus unlawfully harming Sucampo shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171228005446/en/
